Convergence between global BCG vaccination and COVID‐19 pandemic

Removing barriers to global pandemic influenza vaccination.

This article clarifies the regulatory issues surrounding influenza pandemic vaccine for the larger policy community and describes the need for regulatory harmonization. Vaccination would save lives in an influenza pandemic, but a lack of global manufacturing capacity will leave most of the world without access to vaccine. Capacity can be expanded if governments harmonize their regulatory polici...

BCG Vaccination

BCG VACCINATION. Studies by the WHO Tuberculosis Research Office, Copenhagen. Report prepared under the direction of Lydia B. Edwards and Carroll E. Palmer with the assistance of Knut Magnus. Monograph Series No. 12. Geneva, World Health Organization, 1953. 307 pp. 15/-, $3.00, Sw. fr. 12.This monograph contains the results of an inquiry into the variable factors that affect BCG vaccination. Th...

The BCG World Atlas: A Database of Global BCG Vaccination Policies and Practices

Tuberculosis (TB) remains one of the major causes of infectious morbidity and mortality globally, claiming millions of lives every year. Approximately one-third of the world’s population is estimated to be infected with Mycobacterium tuberculosis, giving rise to 9.4 million new cases of active TB disease each year [1]. The majority of the TB burden exists in 22 high-burden countries, but with i...

BCG vaccination and the EPI.

BCG vaccination for newborns has been compulsory by law in the RSA since 1973. From limited published information, it appears that coverage has now reached more than 80%. However, the effectiveness of the vaccinations in terms of disease prevention in the young is unknown. Small studies indicate protection of approximately 60% against all forms of tuberculosis in infants, but this figure is not...

Controversy over BCG Vaccination